Glendon E. French III - 01 Dec 2025 Form 4 Insider Report for Pulmonx Corp (LUNG)

Reporting relationship: President and CEO, Director
Issuer ticker: LUNG
Reported as of: 01 Dec 2025
Net transaction value: -$13,824
SEC form: 4
Accepted by SEC: 03 Dec 2025, 19:51:47 UTC
Prior SEC filing: 04 Jun 2025
Next SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ David Aaron Lehman, Attorney-in-Fact

Key filing fact

Glendon E. French III filed Form 4 for Pulmonx Corp (LUNG) on 03 Dec 2025.

Key facts

This page summarizes Glendon E. French III's Form 4 filing for Pulmonx Corp (LUNG).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Dec 2025, 19:51.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: -$13,824.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001805624 Primary reporting owner

French Glendon E. III

Relationship: President and CEO, Director
Address: C/O PULMONX CORPORATION, 700 CHESAPEAKE DRIVE, REDWOOD CITY
Signature: /s/ David Aaron Lehman, Attorney-in-Fact
Signature date: 02 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LUNG transaction

Common Stock

Sale

Transaction value: $3,963
Shares: -2,524
Change %: -0.88%
Price: $1.57
Shares after: 283,605
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F1

LUNG transaction

Common Stock

Sale

Transaction value: $9,861
Shares: -6,281
Change %: -2.2%
Price: $1.57
Shares after: 277,324
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F2

LUNG transaction

Common Stock

Award

Transaction value: $0
Shares: +1,200,000
Change %: +433%
Price: $0.000000
Shares after: 1,477,324
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F3

LUNG holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 742,998
Date: 01 Dec 2025
Ownership: By trust
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LUNG transaction Derivative

Performance Stock Units

Award

Transaction value: $0
Shares: +800,000
Change %
Price: $0.000000
Shares after: 800,000
Date: 01 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 800,000
Exercise price
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022.

Footnote F2

These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.

Footnote F3

Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of December 1, 2025.

Footnote F4

The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.

Footnote F5

Each Performance Stock Unit represents a contingent right to receive one share of the Issuer's common stock. The Performance Stock Units vest upon meeting the following two conditions: (a) upon the Issuer's common stock achieving a specified price per share and (b) with respect to 33% on the one year following the grant date of December 1, 2025 and the remainder in eight equal quarterly installments.